Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 6270 |
| PDBID: | 8GPJ |
| Chains: | DE_V |
| Organism: | Homo sapiens |
| Method: | EM |
| Resolution (Å): | 3.50 |
| Reference: | 10.1038/s41467-023-40321-x |
| Antibody | |
| Antibody: | 8ANC195 Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | HIV-1 X16 uncleaved prefusion-optimized (UFO) envelope glycoprotein - gp41 |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Heavy Chain: D
Mutation: NULL
| >8GPJ_D|Chain A, C[auth D], E[auth H]|8ANC195 Fab heavy chain|Homo sapiens (9606) QIHLVQSGTEVKKPGSSVTVSCKAYGVNTFGLYAVNWVRQAPGQSLEYIGQIWRWKSSASHHFRGRVLISAVDLTGSSPPISSLEIKDLTSDDTAVYFCTTTSTYDKWSGLHHDGVMAFSSWGQGTLISVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC |
Light Chain: E
Mutation: NULL
| >8GPJ_E|Chain B[auth C], D[auth E], F[auth L]|8ANC195 Fab light chain|Homo sapiens (9606) DIQMTQSPSTLSASIGDTVRISCRASQSITGNWVAWYQQRPGKAPRLLIYRGAALLGGVPSRFSGSAAGTDFTLTIGNLQAEDFGTFYCQQYDTYPGTFGQGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Antigen
Chain: V
Mutation: NULL
| >8GPJ_V|Chain G[auth U], H[auth V], I[auth W], J[auth X], K[auth Y], L[auth Z]|X16 UFO gp41|Homo sapiens (9606) NLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEMVLENVTENFNMWKNEMVNQMHEDVISLWDQSLKPCVKLTPLCVTLDCTTVNSNSSSNSSNSSGNSNSTLEDMQEMKNCSFNTTTELRDKKQKVYALFYKLDIVPLSNNSSEYRLINCNTSAITQACPKVSFDPIPIHYCTPAGYALLKCNDKRFNGTGPCHNVSTVQCTHGIKPVVSTQLLLNGSLAEKEIIVRSENLTNNVKTIIVHLNKSVEIVCTRPGNNTRKSIRIGPGQTFYATGDIIGDIRQAHCNISRGDWEETLHNVRKNLAEHFQNKTIQFASSSGGDLEITTHSFNCRGEFFYCNTSGLFNSTYMPNSTFNGTESNLTITIPCRIKQIINMWQEVGRAMYAPPIAGNITCKSNITGLLLVRDGGKESNSTEIFRPGGGDMRDNWRSELYKYKVVEIKPLGVAPTECKRRVVEGGGGSGGGGSAVGIGAVFLGFLGVAGSTMGAASVALTVQARQLLSGNPDWLPDMTVWGIKQLQTRVLAIERYLKDQQLLGIWGCSGKLICCTAVPWNSSWSNKSQTEIWNNMTWMQWDEEISNYTATIYRLLEVSQNQQERNEKDLLALD |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| Chain residues position delta_SASA
: residuesposition D: LYS106 TRP107 SER108 GLY109 HIS112 ASP113 E: SER27 THR29 GLY30 ASN31 TRP32 ARG50 ALA67 GLY68 ASP92 V: SER613 TRP614 SER615 ASN616 LYS617 MET629 GLN630 ASP632 GLU633 GLU634 SER636 ASN637 TYR638 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 6 Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 6 Å from any atom.
Interacting residues (Atom distance based)
